Exosome‐related lncRNA score: A value‐based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma

Zhan Yang,Xiaoting Zhang,Ning Zhan,Lining Lin,Jingyu Zhang,Lianjie Peng,Tao Qiu,Yaxian Luo,Chundi Liu,Chaoran Pan,Junhao Hu,Yifan Ye,Zilong Jiang,Xinyu Liu,Mouyuan Sun,Yan Zhang

DOI: https://doi.org/10.1002/cam4.7308

IF: 4.711

2024-05-30

Cancer Medicine

Abstract:Exosome‐related lncRNAs potentially involved in ccRCC pathogenesis with distinctive prognosis and management strategy. Based on four key lncRNAs (EMX2OS, AC026401.3, AL161835.1, and AC018690.1), we constructed an exosome‐related lncRNAs score to evaluate its independent prognostic value for ccRCC patients. As the most important ERLR among the four key ERLRs, EMX2OS was screened through mechanical learning and clinical validation, and act as a ceRNA to mediate its downstream network. To further analyze immune and drug sensitivity responses to ccRCC, we finally focus on the effect of EMX2OS on hsa‐miR‐31‐5p/TLN2 axis. ERLR: exosome‐related lncRNA; GG: Golgi apparatus; MVB: multivesicular body; ICI: immune checkpoint inhibitors; ccRCC: clear cell renal cell carcinoma. Background Exosomes play a crucial role in intercellular communication in clear cell renal cell carcinoma (ccRCC), while the long non‐coding RNAs (lncRNAs) are implicated in tumorigenesis and progression. Aims The purpose of this study is to construction a exosomes‐related lncRNA score and a ceRNA network to predict the response to immunotherapy and potential targeted drug in ccRCC. Methods Data of ccRCC patients were obtained from the TCGA database. Pearson correlation analysis was used to identify eExosomes‐related lncRNAs (ERLRs) from Top10 exosomes‐related genes that have been screened. The entire cohort was randomly divided into a training cohort and a validation cohort in equal scale. LASSO regression and multivariate cox regression was used to construct the ERLRs‐based score. Differences in clinicopathological characteristics, immune microenvironment, immune checkpoints, and drug susceptibility between the high‐ and low‐risk groups were also investigated. Finally, the relevant ceRNA network was constructed by machine learning to analyze their potential targets in immunotherapy and drug use of ccRCC patients. Results A score consisting of 4ERLRs was identified, and patients with higher ERLRs‐based score tended to have a worse prognosis than those with lower ERLRs‐based score. ROC curves and multivariate Cox regression analysis demonstrated that the score could be considered as a risk factor for prognosis in both training and validation cohorts. Moreover, patients with high scores are predisposed to experience poor overall survival, a larger prevalence of advanced stage (III‐IV), a greater tumor mutational burden, a higher infiltration of immunosuppressive cells, and a greater likelihood of responding favorably to immunotherapy. The importance of EMX2OS was determined by mechanical learning, and the ceRNA network was constructed, and EMX2OS may be a potential therapeutic target, possibly exerting its function through the EMX2OS/hsa‐miR‐31‐5p/TLN2 axis. Conclusions Based on machine learning, a novel ERLRs‐based score was constructed for predicting the survival of ccRCC patients. The ERLRs‐based score is a promising potential independent prognostic factor that is closely correlated with the immune microenvironment and clinicopathological characteristics. Meanwhile, we screened out key lncRNAEMX2OS and identified the EMX2OS/hsa‐miR‐31‐5p/TLN2 axis, which may provide new clues for the targeted therapy of ccRCC.

oncology